Ann: Quarterly Appendix 4C and Activities Report, page-2

Dimerix ended the quarter with cash of $14.8 million ($6.8 million at 30 September 2023), with net operating cash inflows for the period of $7.8 million ($1.5 million net operating cash inflows in the prior quarter). Cash inflow for the period predominately related to the AU$10.8 million up front payment received from Advanz Pharma in relation to the exclusive license agreement for the European Economic Area, the UK, Switzerland, Canada, Australia, and New Zealand for the commercialisation of Dimerix’ Phase 3 drug candidate DMX-200 for the treatment of FSGS7.

Offsettingcash inflows, Dimerix incurred $3.4 million of operating expenditure, predominately related to Clinical and CMC costs related to the Phase 3 FSGS Study.Additionally, during the quarter,

Dimerix received approximately $374,000 in relation to the exercise of unlisted options (the material terms of the unlisted options are set out in the Prospectus' as lodged with ASIC and released to ASX on 4 May 2023 and 26 June 2023).